According to a recent LinkedIn post from Forge Biologics, Chief Regulatory Officer Christopher Shilling is scheduled to speak at the AAV Gene Therapy Safety: Mechanisms and Risk Mitigation Workshop in Orlando, Florida, on March 7. The workshop is described as being hosted by the American Society of Gene & Cell Therapy and the Alliance for Regenerative Medicine and aims to convene leaders focused on advancing AAV safety.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Shilling plans to address recent U.S. regulatory trends influencing the future of gene therapy, suggesting Forge’s leadership is actively engaged with evolving oversight in this space. For investors, this visible participation in expert regulatory discussions may signal that Forge is positioning itself as a knowledgeable partner on compliance and safety, factors that can be critical differentiators for securing and retaining gene therapy manufacturing clients.
The message also reiterates Forge Biologics’ emphasis on manufacturing gene therapies with safety as a priority and supporting meaningful patient outcomes. While the post does not provide financial metrics, capacity details, or new commercial agreements, the focus on regulatory insight and safety may support the company’s reputation in the competitive CDMO segment of gene and cell therapy, potentially reinforcing its long‑term business development prospects as regulatory expectations for AAV programs tighten.